- Conditions
- Moderate to Severe Asthma
- Interventions
- Dupilumab, Benralizumab
- Biological
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 67
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 8
- States / cities
- North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
- Interventions
- Dupilumab SAR231893, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Roseville, California • Stockton, California • Denver, Colorado + 7 more
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
- Interventions
- PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more
- Conditions
- Dermatitis Atopic
- Interventions
- Dupilumab SAR231893
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Denver, Colorado
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Dermatitis Atopic
- Interventions
- Dupilumab (SAR231893)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • East Windsor, New Jersey
- Conditions
- Pruritis
- Interventions
- Dupilumab, Placebo
- Drug · Other
- Lead sponsor
- Akron Children's Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Akron, Ohio
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more
- Conditions
- Alopecia Areata
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 5
- States / cities
- Irvine, California • San Diego, California • Chicago, Illinois + 1 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Charleston, South Carolina • Charlottesville, Virginia
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps, Asthma
- Interventions
- Dupilumab, Omalizumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Eosinophilic Esophagitis (EoE) food introduction-1st, Eosinophilic Esophagitis (E0E) food introduction-2nd, Eosinophilic Esophagitis (EoE) Food introduction-3rd dose, Dupilumab
- Dietary Supplement · Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- COVID-19
- Interventions
- Dupilumab, Placebo
- Biological · Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Dupilumab, Cemiplimab
- Biological
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo
- Drug · Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 92
- States / cities
- Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab SAR231893
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Asthma
- Interventions
- Dupilumab SAR231893 (REGN668)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 35
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more